Cargando…
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients
BACKGROUND: Frail patients are considered at relevant risk of complications due to coronavirus disease 2019 (COVID-19) infection and, for this reason, are prioritized candidates for vaccination. As these patients were originally not included in the registration trials, fear related to vaccine advers...
Autores principales: | Lupo-Stanghellini, Maria Teresa, Di Cosimo, Serena, Costantini, Massimo, Monti, Sara, Mantegazza, Renato, Mantovani, Alberto, Salvarani, Carlo, Zinzani, Pier Luigi, Inglese, Matilde, Ciceri, Fabio, Apolone, Giovanni, Ciliberto, Gennaro, Baldanti, Fausto, Morrone, Aldo, Sinno, Valentina, Locatelli, Franco, Notari, Stefania, Turola, Elena, Giannarelli, Diana, Silvestris, Nicola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969577/ https://www.ncbi.nlm.nih.gov/pubmed/35371993 http://dx.doi.org/10.3389/fonc.2022.855723 |
Ejemplares similares
-
Safety of third dose of COVID-19 vaccination in frail patients: Results from the prospective Italian VAX4FRAIL study
por: Di Cosimo, Serena, et al.
Publicado: (2022) -
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
por: Rescigno, Maria, et al.
Publicado: (2023) -
Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study
por: Corradini, Paolo, et al.
Publicado: (2022) -
COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial
por: Agrati, Chiara, et al.
Publicado: (2021) -
Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research
por: Silvestris, Nicola, et al.
Publicado: (2017)